- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 439
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Subjects
- Interventions
- LEM5, LEM10, ZOL, PBO
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Raleigh, North Carolina + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- Lecanemab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Pediatrics, Solid Tumors
- Interventions
- Eribulin Mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Golvatinib, Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Urothelial Carcinoma
- Interventions
- Pembrolizumab, Lenvatinib, Placebo for lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Clovis, California • Orange, California + 18 more
- Conditions
- Epilepsy
- Interventions
- Not listed
- Lead sponsor
- The Epilepsy Study Consortium
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Iron Deficiency Anemia, Helicobacter Pylori Infection
- Interventions
- H. pylori treatment
- Drug
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Procedural Sedation, Regional Anesthesia Block, Orthopedic Surgery
- Interventions
- Fospropofol disodium, Placebo + Midazolam, Fentanyl
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- Eribulin, Cyclophosphamide, Docetaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 15
- States / cities
- Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 12 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- MORAb-202
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Orange, California • Lone Tree, Colorado • Clermont, Florida + 10 more
- Conditions
- P-glycoprotein, Healthy Volunteers
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Decitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Decitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • St Louis, Missouri
- Conditions
- Refractory Partial Seizures
- Interventions
- E2007 (perampanel), Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
- Conditions
- Breast Cancer
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- Pediatric Epileptic Syndrome, Partial-onset Seizures
- Interventions
- Perampanel Oral Suspension, Perampanel Tablet
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more
- Conditions
- Persistent or Recurrent Cutaneous T-Cell Lymphoma
- Interventions
- E7777 9 mcg/kg
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 12 more
- Conditions
- Insomnia
- Interventions
- Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,006 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 60
- States / cities
- Jasper, Alabama • Glendale, Arizona • Little Rock, Arkansas + 49 more
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Timeline
- Ends 2015
- U.S. locations
- 13
- States / cities
- La Jolla, California • Stanford, California • Torrance, California + 10 more
- Conditions
- Refractory Solid Tumors, Lymphomas
- Interventions
- Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Decitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Boca Raton, Florida + 17 more
- Conditions
- Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- Denileukin diftitox
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Dementia, Vascular
- Interventions
- Donepezil Hydrochloride
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 41 Years and older
- Enrollment
- 974 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 5
- States / cities
- Hot Springs, Arkansas • St. Petersburg, Florida • Peoria, Illinois + 2 more